IN2014CN04652A - - Google Patents
Info
- Publication number
- IN2014CN04652A IN2014CN04652A IN4652CHN2014A IN2014CN04652A IN 2014CN04652 A IN2014CN04652 A IN 2014CN04652A IN 4652CHN2014 A IN4652CHN2014 A IN 4652CHN2014A IN 2014CN04652 A IN2014CN04652 A IN 2014CN04652A
- Authority
- IN
- India
- Prior art keywords
- antibodies
- igf
- treatment
- gigantism
- ghr
- Prior art date
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
- C07K16/2869—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against hormone receptors
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
- A61K39/39533—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals
- A61K39/39558—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals against tumor tissues, cells, antigens
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P13/00—Drugs for disorders of the urinary system
- A61P13/12—Drugs for disorders of the urinary system of the kidneys
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
- A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P5/00—Drugs for disorders of the endocrine system
- A61P5/06—Drugs for disorders of the endocrine system of the anterior pituitary hormones, e.g. TSH, ACTH, FSH, LH, PRL, GH
- A61P5/08—Drugs for disorders of the endocrine system of the anterior pituitary hormones, e.g. TSH, ACTH, FSH, LH, PRL, GH for decreasing, blocking or antagonising the activity of the anterior pituitary hormones
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
- C07K16/2863—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against receptors for growth factors, growth regulators
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
- C07K2317/24—Immunoglobulins specific features characterized by taxonomic origin containing regions, domains or residues from different species, e.g. chimeric, humanized or veneered
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/40—Immunoglobulins specific features characterized by post-translational modification
- C07K2317/41—Glycosylation, sialylation, or fucosylation
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
- C07K2317/76—Antagonist effect on antigen, e.g. neutralization or inhibition of binding
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
- C07K2317/92—Affinity (KD), association rate (Ka), dissociation rate (Kd) or EC50 value
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Medicinal Chemistry (AREA)
- Organic Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Immunology (AREA)
- Engineering & Computer Science (AREA)
- Animal Behavior & Ethology (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Pharmacology & Pharmacy (AREA)
- Bioinformatics & Cheminformatics (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Diabetes (AREA)
- Molecular Biology (AREA)
- Biomedical Technology (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Genetics & Genomics (AREA)
- Biophysics (AREA)
- Biochemistry (AREA)
- Endocrinology (AREA)
- Mycology (AREA)
- Oncology (AREA)
- Epidemiology (AREA)
- Microbiology (AREA)
- Rheumatology (AREA)
- Neurology (AREA)
- Pulmonology (AREA)
- Pain & Pain Management (AREA)
- Obesity (AREA)
- Emergency Medicine (AREA)
- Urology & Nephrology (AREA)
- Orthopedic Medicine & Surgery (AREA)
- Hematology (AREA)
- Physical Education & Sports Medicine (AREA)
- Peptides Or Proteins (AREA)
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US201161579618P | 2011-12-22 | 2011-12-22 | |
PCT/IB2012/057151 WO2013093707A1 (en) | 2011-12-22 | 2012-12-10 | Human growth hormone receptor antagonist antibodies and methods of use thereof |
Publications (1)
Publication Number | Publication Date |
---|---|
IN2014CN04652A true IN2014CN04652A (de) | 2015-09-18 |
Family
ID=47436138
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
IN4652CHN2014 IN2014CN04652A (de) | 2011-12-22 | 2012-12-10 |
Country Status (16)
Country | Link |
---|---|
US (1) | US9249224B2 (de) |
EP (1) | EP2794659A1 (de) |
JP (1) | JP2015502975A (de) |
KR (1) | KR20140102710A (de) |
CN (1) | CN104169301A (de) |
AU (1) | AU2012356206A1 (de) |
BR (1) | BR112014014824A2 (de) |
CA (1) | CA2859472A1 (de) |
HK (1) | HK1204328A1 (de) |
IL (1) | IL233119A0 (de) |
IN (1) | IN2014CN04652A (de) |
MX (1) | MX2014007644A (de) |
RU (1) | RU2014123030A (de) |
SG (1) | SG11201402828XA (de) |
WO (1) | WO2013093707A1 (de) |
ZA (1) | ZA201404735B (de) |
Families Citing this family (6)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
JP6556758B2 (ja) * | 2014-01-24 | 2019-08-07 | チャーチ、ウィリアム、アール. | 黄色ブドウ球菌特異的抗体、それを用いた治療方法及び検出方法 |
JP6930916B2 (ja) * | 2015-02-12 | 2021-09-01 | ユニヴァーシティ オブ サザン カリフォルニアUniversity of Southern California | 疾患予防および治療における成長ホルモン受容体の遮断剤 |
US11473088B2 (en) * | 2016-12-02 | 2022-10-18 | Ohio University | Method of treating cancer and method of sensitizing cancer cells to the action of chemotherapeutic agents via growth hormone receptor antagonists or knock down |
EP3759145A4 (de) * | 2018-02-26 | 2022-03-09 | Minerva Biotechnologies Corporation | Diagnoseverfahren unter verwendung von anti-muc1*-antikörpern |
WO2020069208A1 (en) * | 2018-09-27 | 2020-04-02 | The Regents Of The University Of California | Prevention and treatment of osteoarthritis by inhibition of insulin growth factor-1 signaling |
US11345744B2 (en) | 2019-05-07 | 2022-05-31 | William R Church | Antibody specific to Staphylococcus aureus, therapeutic method and detection method using same |
Family Cites Families (66)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US3773919A (en) | 1969-10-23 | 1973-11-20 | Du Pont | Polylactide-drug mixtures |
FR2413974A1 (fr) | 1978-01-06 | 1979-08-03 | David Bernard | Sechoir pour feuilles imprimees par serigraphie |
US4485045A (en) | 1981-07-06 | 1984-11-27 | Research Corporation | Synthetic phosphatidyl cholines useful in forming liposomes |
US4816567A (en) | 1983-04-08 | 1989-03-28 | Genentech, Inc. | Recombinant immunoglobin preparations |
US4544545A (en) | 1983-06-20 | 1985-10-01 | Trustees University Of Massachusetts | Liposomes containing modified cholesterol for organ targeting |
US5807715A (en) | 1984-08-27 | 1998-09-15 | The Board Of Trustees Of The Leland Stanford Junior University | Methods and transformed mammalian lymphocyte cells for producing functional antigen-binding protein including chimeric immunoglobulin |
US4754065A (en) | 1984-12-18 | 1988-06-28 | Cetus Corporation | Precursor to nucleic acid probe |
US4683195A (en) | 1986-01-30 | 1987-07-28 | Cetus Corporation | Process for amplifying, detecting, and/or-cloning nucleic acid sequences |
US4683202A (en) | 1985-03-28 | 1987-07-28 | Cetus Corporation | Process for amplifying nucleic acid sequences |
US4676980A (en) | 1985-09-23 | 1987-06-30 | The United States Of America As Represented By The Secretary Of The Department Of Health And Human Services | Target specific cross-linked heteroantibodies |
US4777127A (en) | 1985-09-30 | 1988-10-11 | Labsystems Oy | Human retrovirus-related products and methods of diagnosing and treating conditions associated with said retrovirus |
GB8601597D0 (en) | 1986-01-23 | 1986-02-26 | Wilson R H | Nucleotide sequences |
US4800159A (en) | 1986-02-07 | 1989-01-24 | Cetus Corporation | Process for amplifying, detecting, and/or cloning nucleic acid sequences |
GB8702816D0 (en) | 1987-02-07 | 1987-03-11 | Al Sumidaie A M K | Obtaining retrovirus-containing fraction |
US5219740A (en) | 1987-02-13 | 1993-06-15 | Fred Hutchinson Cancer Research Center | Retroviral gene transfer into diploid fibroblasts for gene therapy |
US5057417A (en) | 1987-06-12 | 1991-10-15 | Genentech, Inc. | Compositions and methods for the synthesis of growth hormone receptor and growth hormone binding protein |
US5422120A (en) | 1988-05-30 | 1995-06-06 | Depotech Corporation | Heterovesicular liposomes |
AP129A (en) | 1988-06-03 | 1991-04-17 | Smithkline Biologicals S A | Expression of retrovirus gag protein eukaryotic cells |
US5047335A (en) | 1988-12-21 | 1991-09-10 | The Regents Of The University Of Calif. | Process for controlling intracellular glycosylation of proteins |
EP0832980B1 (de) | 1989-01-23 | 2002-06-19 | Chiron Corporation | Rekombinanttherapien für Infektionen und hyperproliferative Störungen |
US6673776B1 (en) | 1989-03-21 | 2004-01-06 | Vical Incorporated | Expression of exogenous polynucleotide sequences in a vertebrate, mammal, fish, bird or human |
US5703055A (en) | 1989-03-21 | 1997-12-30 | Wisconsin Alumni Research Foundation | Generation of antibodies through lipid mediated DNA delivery |
JP3250802B2 (ja) | 1989-03-21 | 2002-01-28 | バイカル・インコーポレイテッド | 脊椎動物における外因性ポリヌクレオチド配列の発現 |
EP0479909B1 (de) | 1989-06-29 | 1996-10-30 | Medarex, Inc. | Bispezifische reagenzien für die aids-therapie |
AU648261B2 (en) | 1989-08-18 | 1994-04-21 | Novartis Vaccines And Diagnostics, Inc. | Recombinant retroviruses delivering vector constructs to target cells |
US5585362A (en) | 1989-08-22 | 1996-12-17 | The Regents Of The University Of Michigan | Adenovirus vectors for gene therapy |
US5013556A (en) | 1989-10-20 | 1991-05-07 | Liposome Technology, Inc. | Liposomes with enhanced circulation time |
ZA911974B (en) | 1990-03-21 | 1994-08-22 | Res Dev Foundation | Heterovesicular liposomes |
US5427908A (en) | 1990-05-01 | 1995-06-27 | Affymax Technologies N.V. | Recombinant library screening methods |
US5278299A (en) | 1991-03-18 | 1994-01-11 | Scripps Clinic And Research Foundation | Method and composition for synthesizing sialylated glycosyl compounds |
EP0586505A1 (de) | 1991-05-14 | 1994-03-16 | Repligen Corporation | Heterokonjugat-antikörper zur behandlung von hiv-infektionen |
GB9115364D0 (en) | 1991-07-16 | 1991-08-28 | Wellcome Found | Antibody |
WO1993003769A1 (en) | 1991-08-20 | 1993-03-04 | THE UNITED STATES OF AMERICA, represented by THE SECRETARY, DEPARTEMENT OF HEALTH AND HUMAN SERVICES | Adenovirus mediated transfer of genes to the gastrointestinal tract |
CA2078539C (en) | 1991-09-18 | 2005-08-02 | Kenya Shitara | Process for producing humanized chimera antibody |
DK0605522T3 (da) | 1991-09-23 | 2000-01-17 | Medical Res Council | Fremgangsmåde til fremstilling af humaniserede antistoffer |
ES2136092T3 (es) | 1991-09-23 | 1999-11-16 | Medical Res Council | Procedimientos para la produccion de anticuerpos humanizados. |
WO1993010218A1 (en) | 1991-11-14 | 1993-05-27 | The United States Government As Represented By The Secretary Of The Department Of Health And Human Services | Vectors including foreign genes and negative selective markers |
WO1993010260A1 (en) | 1991-11-21 | 1993-05-27 | The Board Of Trustees Of The Leland Stanford Junior University | Controlling degradation of glycoprotein oligosaccharides by extracellular glycosisases |
GB9125623D0 (en) | 1991-12-02 | 1992-01-29 | Dynal As | Cell modification |
FR2688514A1 (fr) | 1992-03-16 | 1993-09-17 | Centre Nat Rech Scient | Adenovirus recombinants defectifs exprimant des cytokines et medicaments antitumoraux les contenant. |
US5733743A (en) | 1992-03-24 | 1998-03-31 | Cambridge Antibody Technology Limited | Methods for producing members of specific binding pairs |
WO1993025234A1 (en) | 1992-06-08 | 1993-12-23 | The Regents Of The University Of California | Methods and compositions for targeting specific tissue |
CA2137361A1 (en) | 1992-06-10 | 1993-12-23 | W. French Anderson | Vector particles resistant to inactivation by human serum |
GB2269175A (en) | 1992-07-31 | 1994-02-02 | Imperial College | Retroviral vectors |
DE69308573T2 (de) | 1992-08-17 | 1997-08-07 | Genentech Inc | Bispezifische immunoadhesine |
WO1994012649A2 (en) | 1992-12-03 | 1994-06-09 | Genzyme Corporation | Gene therapy for cystic fibrosis |
US5981568A (en) | 1993-01-28 | 1999-11-09 | Neorx Corporation | Therapeutic inhibitor of vascular smooth muscle cells |
AU6818094A (en) | 1993-04-22 | 1994-11-08 | Depotech Corporation | Cyclodextrin liposomes encapsulating pharmacologic compounds and methods for their use |
WO1995000655A1 (en) | 1993-06-24 | 1995-01-05 | Mc Master University | Adenovirus vectors for gene therapy |
US6015686A (en) | 1993-09-15 | 2000-01-18 | Chiron Viagene, Inc. | Eukaryotic layered vector initiation systems |
ATE257176T1 (de) | 1993-09-15 | 2004-01-15 | Chiron Corp | Rekombinanter alphavirus vektor |
EP1637608B1 (de) | 1993-10-25 | 2009-07-22 | CANJI, Inc. | Rekombinanter Adenoviren-Vektor und Verfahren zur Verwendung |
ATE196248T1 (de) | 1993-11-16 | 2000-09-15 | Skyepharma Inc | Vesikel mit gesteuerter wirkstofffreisetzung |
US6436908B1 (en) | 1995-05-30 | 2002-08-20 | Duke University | Use of exogenous β-adrenergic receptor and β-adrenergic receptor kinase gene constructs to enhance myocardial function |
ES2297831T3 (es) | 1994-05-09 | 2008-05-01 | Oxford Biomedica (Uk) Limited | Vectores retroviricos que presentan una tasa de recombinacion reducida. |
AU4594996A (en) | 1994-11-30 | 1996-06-19 | Chiron Viagene, Inc. | Recombinant alphavirus vectors |
US6265150B1 (en) | 1995-06-07 | 2001-07-24 | Becton Dickinson & Company | Phage antibodies |
ATE424463T1 (de) | 1996-05-06 | 2009-03-15 | Oxford Biomedica Ltd | Rekombinationsunfähige retrovirale vektoren |
US6376471B1 (en) | 1997-10-10 | 2002-04-23 | Johns Hopkins University | Gene delivery compositions and methods |
GB9809951D0 (en) | 1998-05-08 | 1998-07-08 | Univ Cambridge Tech | Binding molecules |
US20020142374A1 (en) | 1998-08-17 | 2002-10-03 | Michael Gallo | Generation of modified molecules with increased serum half-lives |
AU3734900A (en) | 1999-03-09 | 2000-09-28 | University Of Southern California | Method of promoting myocyte proliferation and myocardial tissue repair |
HUE026089T2 (hu) | 2002-12-24 | 2016-05-30 | Rinat Neuroscience Corp | NGF elleni antitestek és eljárás alkalmazásukra |
EP1871417B1 (de) | 2005-04-15 | 2013-09-11 | Precision Biologics, Inc. | Rekombinante monoklonale antikörper und entsprechende antigene für kolon- und pankreaskarzinom |
WO2007100640A2 (en) * | 2006-02-21 | 2007-09-07 | The Regents Of The University Of Michigan | Growth hormone receptor antagonist cancer treatment |
MX2008012146A (es) * | 2006-03-28 | 2008-10-03 | Biogen Idec Inc | Anticuerpos anti-receptor 1 de factor de crecimiento tipo insulina (igf-1r) y uso de los mismos. |
-
2012
- 2012-12-10 IN IN4652CHN2014 patent/IN2014CN04652A/en unknown
- 2012-12-10 KR KR1020147017014A patent/KR20140102710A/ko not_active Application Discontinuation
- 2012-12-10 SG SG11201402828XA patent/SG11201402828XA/en unknown
- 2012-12-10 CN CN201280070288.9A patent/CN104169301A/zh active Pending
- 2012-12-10 RU RU2014123030A patent/RU2014123030A/ru not_active Application Discontinuation
- 2012-12-10 AU AU2012356206A patent/AU2012356206A1/en not_active Abandoned
- 2012-12-10 JP JP2014548270A patent/JP2015502975A/ja active Pending
- 2012-12-10 WO PCT/IB2012/057151 patent/WO2013093707A1/en active Application Filing
- 2012-12-10 MX MX2014007644A patent/MX2014007644A/es unknown
- 2012-12-10 EP EP12806702.2A patent/EP2794659A1/de not_active Withdrawn
- 2012-12-10 CA CA2859472A patent/CA2859472A1/en not_active Abandoned
- 2012-12-10 US US14/367,483 patent/US9249224B2/en not_active Expired - Fee Related
- 2012-12-10 BR BR112014014824A patent/BR112014014824A2/pt not_active IP Right Cessation
-
2014
- 2014-06-12 IL IL233119A patent/IL233119A0/en unknown
- 2014-06-26 ZA ZA2014/04735A patent/ZA201404735B/en unknown
-
2015
- 2015-05-20 HK HK15104823.8A patent/HK1204328A1/xx unknown
Also Published As
Publication number | Publication date |
---|---|
KR20140102710A (ko) | 2014-08-22 |
MX2014007644A (es) | 2014-09-26 |
EP2794659A1 (de) | 2014-10-29 |
BR112014014824A2 (pt) | 2019-09-24 |
WO2013093707A1 (en) | 2013-06-27 |
JP2015502975A (ja) | 2015-01-29 |
SG11201402828XA (en) | 2014-10-30 |
AU2012356206A1 (en) | 2014-06-26 |
RU2014123030A (ru) | 2016-02-20 |
US20140356359A1 (en) | 2014-12-04 |
HK1204328A1 (en) | 2015-11-13 |
ZA201404735B (en) | 2016-10-26 |
IL233119A0 (en) | 2014-07-31 |
US9249224B2 (en) | 2016-02-02 |
CA2859472A1 (en) | 2013-06-27 |
CN104169301A (zh) | 2014-11-26 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
IN2014CN04652A (de) | ||
PH12016501728A1 (en) | Anti-angiogenesis therapy for the treatment of ovarian cancer | |
MX2018010331A (es) | Agentes de ligacion al factor de crecimiento endotelial vascular/ligando 4 similar a delta (vegf/dll4) y usos de los mismos. | |
TN2012000555A1 (en) | Antibodies to human gdf8 | |
MX2015005874A (es) | Anticuerpos especificos del factor de crecimiento b derivados de plaquetas y composiciones y usos de estos. | |
MX2010004327A (es) | Anticuerpos anti-vegf completamente humanos y metodos de uso. | |
NZ599737A (en) | Il-17a antagonists | |
PH12014502437A1 (en) | Anti-egfr antibodies and uses threof | |
MX341076B (es) | Formulaciones estables de anticuerpos para el receptor humano pd-1 de meurte programada y tratamientos relacionados. | |
AU2011332810A8 (en) | Anti-IL-6 antibodies for the treatment of oral mucositis | |
MY167920A (en) | HUMAN ANTIBODIES TO GFRα3 AND METHODS OF USE THEREOF | |
EP2614085A4 (de) | Anti-il-1-antikörper und verfahren zu ihrer verwendung | |
PH12015501864A1 (en) | Methods for treating osteogenesis imperfecta | |
WO2011112867A8 (en) | The use of fenoterol and fenoterol analogues in the treatment of glioblastomas and astrocytomas | |
AU2014306956B2 (en) | Methods for reducing exacerbation rates of asthma using benralizumab | |
MX360774B (es) | Antagonistas de progesterona. | |
UA106529C2 (uk) | Гуманізоване антитіло до cxcr4 для лікування раку | |
MX2014001766A (es) | Anticuerpos de neuregulina y sus usos. | |
PH12015501271B1 (en) | Stabilized insulin-like growth factor polypeptides | |
EP2563398A4 (de) | Wachstumshormonrezeptormangel als ursache einer grösseren abnahme von pro-aging-signalen sowie von krebs und diabetes beim menschen | |
GB201109238D0 (en) | Antibodies | |
NZ702178A (en) | Lingo-2 antagonists for treatment of conditions involving motor neurons | |
NZ754676A (en) | Use of anti-sclerostin antibodies in the treatment of osteogenesis imperfecta | |
EP3524274A3 (de) | Verwendung von hom-1 expression zur verwaltung der behandlung von zellproliferationsstörungen | |
MX2015002465A (es) | Anticuerpos monoclonales para mejorar o inhibir factor de crecimiento 1 similar a insulina (igf-1). |